Ricolinostat (ACY-1215) inhibits HDAC6, resulting in tubulin hyperacetylation [15] and interacts synergistically in combination with bortezomib and carfilzomib to treat lymphoma and multiple myeloma (MM) cells [16–18]. Here, HDAC6 is linked to plasma cell myeloma.